Filtered By:
Specialty: Cardiology
Condition: Diabetes Type 2

This page shows you your search results in order of relevance.

Order by Relevance | Date

Total 574 results found since Jan 2013.

Large-Scale Phenome-Wide Association Study of PCSK9 Variants Demonstrates Protection Against Ischemic Stroke Original Articles
Conclusions: This result represents the first genetic evidence in a large cohort for the protective effect of PCSK9 inhibition on ischemic stroke and corroborates exploratory evidence from clinical trials. PCSK9 inhibition was not associated with variables other than those related to LDL (low-density lipoprotein) cholesterol, atherosclerosis, and type 2 diabetes mellitus, suggesting that other effects are either small or absent.
Source: Circulation: Cardiovascular Genetics - July 11, 2018 Category: Cardiology Authors: Rao, A. S., Lindholm, D., Rivas, M. A., Knowles, J. W., Montgomery, S. B., Ingelsson, E. Tags: Cardiovascular Disease, Diabetes, Type 2, Genetic, Association Studies, Ischemic Stroke Original Articles Source Type: research

Incident Stroke and Its Influencing Factors in Patients With Type 2 Diabetes Mellitus and/or Hypertension: A Prospective Cohort Study
CONCLUSIONS: Patients with T2DM and/or HTN have a higher rate of new stroke and recurrence after 1-year follow-up. Actively identifying the controllable risk factors, such as smoking and physical inactivity, will help reduce the risk of stroke and recurrence in patients with T2DM and HTN.PMID:35224030 | PMC:PMC8863944 | DOI:10.3389/fcvm.2022.770025
Source: Atherosclerosis - February 28, 2022 Category: Cardiology Authors: Wei-Wei Chang Shi-Zao Fei Na Pan Ying-Shui Yao Yue-Long Jin Source Type: research

Effects of Liraglutide on Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus With or Without History of Myocardial Infarction or Stroke.
CONCLUSIONS: In this post hoc analysis of patients with type 2 diabetes mellitus and high cardiovascular risk, liraglutide reduced cardiovascular outcomes both in patients with a history of MI/stroke and in those with established atherosclerotic cardiovascular disease without MI/stroke. The cardiovascular effect appeared neutral in patients with cardiovascular risk factors alone. CLINICAL TRIAL REGISTRATION: URL: https://www.clinicaltrials.gov . Unique identifier: NCT01179048. PMID: 30566004 [PubMed - in process]
Source: Circulation - December 18, 2018 Category: Cardiology Authors: Verma S, Poulter NR, Bhatt DL, Bain SC, Buse JB, Leiter LA, Nauck MA, Pratley RE, Zinman B, Ørsted DD, Monk Fries T, Rasmussen S, Marso SP Tags: Circulation Source Type: research

Effects of Pioglitazone for Secondary Stroke Prevention in Patients with Impaired Glucose Tolerance and Newly Diagnosed Diabetes: The J-SPIRIT Study.
CONCLUSIONS: While this study was too underpowered to determine the effect of pioglitazone, the result failed to show beneficial effects in patients of ischemic stroke or TIA with impaired glucose tolerance and newly diagnosed diabetes. PMID: 26269002 [PubMed - as supplied by publisher]
Source: Journal of Atherosclerosis and Thrombosis - August 15, 2015 Category: Cardiology Tags: J Atheroscler Thromb Source Type: research

Long-Term Risk of Stroke in Patients With Type 1 and Type 2 Diabetes Following Coronary Artery Bypass Grafting Cardiovascular Surgery
Conclusions The long-term risk for stroke after coronary artery bypass grafting was increased in patients with type 1 and type 2 diabetes, compared to patients with no diabetes.
Source: JAHA:Journal of the American Heart Association - November 9, 2015 Category: Cardiology Authors: Nystrom, T., Holzmann, M. J., Sartipy, U. Tags: Cardiovascular Surgery Source Type: research

Protective Effects of Different Classes, Intensity, Cumulative Dose-Dependent of Statins Against Primary Ischemic Stroke in Patients with Type 2 Diabetes Mellitus
AbstractPurpose of ReviewThe aim of this study is to investigate the protective effects of different statin classes, intensity, and cumulative dose-dependent against primary ischemic stroke in patients with T2DM.Recent FindingsThe Cox hazards model was used to evaluate statin use on primary ischemic stroke. Case group: T2DM patients who received statins; control group: T2DM patients who received no statins during the follow-up. Adjusted hazard ratio (aHR) for primary ischemic stroke was 0.45 (95% CI: 0.44 to 0.46). Cox regression analysis showed significant reductions in primary ischemic stroke incidence in users of differ...
Source: Current Atherosclerosis Reports - July 29, 2023 Category: Cardiology Source Type: research

Biomarkers Associated with Ischemic Stroke in Diabetes Mellitus Patients.
In conclusion, hyperglycemia may activate platelets through miR-144 and miR-223 to downregulate IRS-1 and upregulate P2Y12 expression in the platelets of T2DM patients through an IRS-1-PI3K-Akt signaling. Low platelet and plasma miR-223 expression in addition to high platelet and plasma miR-144 expression are risk factors for ischemic stroke in T2DM patients. PMID: 26175178 [PubMed - as supplied by publisher]
Source: Cardiovascular Toxicology - July 15, 2015 Category: Cardiology Authors: Yang S, Zhao J, Chen Y, Lei M Tags: Cardiovasc Toxicol Source Type: research

Omentin-1 is Associated with Carotid Plaque Instability among Ischemic Stroke Patients.
CONCLUSIONS: Among ischemic stroke patients, higher omentin-1 levels were inversely associated with carotid plaque instability, but not associated with moderate-severe carotid stenosis or occlusion. Omentin-1 may represent a biomarker for predicting carotid plaque instability of acute ischemic stroke patients. PMID: 29225325 [PubMed - as supplied by publisher]
Source: Journal of Atherosclerosis and Thrombosis - December 12, 2017 Category: Cardiology Tags: J Atheroscler Thromb Source Type: research

Risk of Ischemic Stroke After an Acute Myocardial Infarction in Patients With Diabetes Mellitus Original Articles
Conclusions— Ischemic stroke is a fairly common complication after an AMI in patients with diabetes mellitus, but the risk of stroke has decreased during recent years. The increased use of evidence-based therapies contributes importantly to this risk reduction, but there is still room for improvement.
Source: Circulation: Cardiovascular Quality and Outcomes - January 21, 2014 Category: Cardiology Authors: Jakobsson, S., Bergstrom, L., Bjorklund, F., Jernberg, T., Soderstrom, L., Mooe, T. Tags: Secondary prevention, Type 1 diabetes, Type 2 diabetes, Acute myocardial infarction, Acute Cerebral Infarction Original Articles Source Type: research

Prolonged P wave duration predicts stroke mortality among type 2 diabetic patients with prevalent non-major macrovascular disease
Conclusions: As an easily measurable factor P wave duration merits further studies with higher number of patients to evaluate its importance in the estimation of stroke risk in type 2 diabetic patients with PNMMVD.
Source: BMC Cardiovascular Disorders - November 25, 2014 Category: Cardiology Authors: Teemu VepsäläinenMarkku LaaksoSeppo LehtoAuni JuutilainenJuhani AiraksinenTapani Rönnemaa Source Type: research

Angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers and the risk of major adverse cardiac events in patients with diabetes and prior stroke: a nationwide study
Conclusion: Our study supports the hypothesis that the risks of MACEs and two additional secondary outcomes in patients with diabetes who survived ischemic stroke did not differ according to ACEI versus ARB use.
Source: Journal of Hypertension - January 30, 2016 Category: Cardiology Tags: ORIGINAL PAPERS: Therapeutic aspects Source Type: research

Causal Associations of Adiposity and Body Fat Distribution with Coronary Heart Disease, Stroke Subtypes and Type 2 Diabetes: A Mendelian Randomization Analysis.
Conclusions -Both general and central adiposity have causal effects on CHD and T2D. Central adiposity may have a stronger effect on stroke risk. Future estimates of the burden of adiposity on health should include measures of central and general adiposity. PMID: 28500271 [PubMed - as supplied by publisher]
Source: Circulation - May 12, 2017 Category: Cardiology Authors: Dale C, Fatemifar G, Palmer T, White J, Prieto-Merino D, Zabaneh D, Engmann JEL, Shah T, Wong A, Warren HR, McLachlan S, Trompet S, Moldovan M, Morris RW, Sofat R, Kumari M, Hyppönen E, Jefferis BJ, Gaunt TR, Ben-Shlomo Y, Zhou A, Gentry-Maharaj A, Ryan Tags: Circulation Source Type: research

Cardiac Outcomes After Ischemic Stroke or TIA: Effects of Pioglitazone in Patients with Insulin Resistance Without Diabetes.
Conclusions -Among patients with insulin resistance without diabetes, pioglitazone reduced the risk for acute coronary syndromes after a recent cerebrovascular event. Pioglitazone appeared to have its most prominent effect in preventing spontaneous type 1 MI's. Clinical Trial Registration - https://clinicaltrials.gov Unique Identifier: NCT00091949 US Food & Drug Administration IND: 64,622; EudraCT#2008-005546-23. PMID: 28246237 [PubMed - as supplied by publisher]
Source: Circulation - February 27, 2017 Category: Cardiology Authors: Young LH, Viscoli CM, Curtis JP, Inzucchi SE, Schwartz GG, Lovejoy AM, Furie KL, Gorman MJ, Conwit RA, Abbott JD, Jacoby DL, Kolansky DM, Pfau SE, Ling FS, Kernan WN, IRIS Investigators Tags: Circulation Source Type: research

Glucagon-like peptide-1 agonists and protection against stroke: A systematic review and meta-analysis
Aim: Type 2 diabetes is associated with an increased risk of stroke and a worse outcome following stroke. Among glucose-lowering modalities only pioglitazone (a thiazolinedione) has been shown to protect against stroke. Nonetheless, evidence from experimental with novel antidiabetic agents, such as glucagon-like peptide-1 (GLP-1) agonists, suggests potential neuroprotective effects, especially if treatment starts before stroke. Thus, we aimed to meta-analyze available evidence regarding the risk of stroke in individuals receiving GLP-1 agonists.
Source: Atherosclerosis - August 1, 2017 Category: Cardiology Authors: Fotios Barkas, Moses Elisaf, Haralampos Milionis Source Type: research